LTRN Q4 2023 Earnings — Lantern Pharma Inc. Revenue & Financial Results | Market Cap Arena

LTRNLantern Pharma Inc.

$31M

Q4 2023 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

-$44,317

Operating Income

-$5M

Net Income

-$4M

EPS (Diluted)

$-0.39

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$3M

Stock-Based Comp.

$150,840

Balance Sheet

Total Assets

$44M

Total Liabilities

$3M

Stockholders' Equity

$41M

Cash & Equivalents

$22M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	-$44,317	$0	—
Operating Income	-$5M	-$4M	-27.5%
Net Income	-$4M	-$3M	-23.8%